Form 4: Lyell Immunopharma VP Sells Over 2,000 Shares

Lyell Immunopharma's VP, Corporate Controller, Veronica Sanchez Bulis, reported selling 2,072 shares of common stock in two separate transactions in late 2025.

Summary

• Veronica Sanchez Bulis, VP, Corporate Controller of Lyell Immunopharma, Inc. (LYEL), reported two sales of common stock.
• On December 24, 2025, Bulis sold 1,136 shares of common stock at a weighted average price of $38.67 per share, with prices ranging from $38.6643 to $38.6751.
• Following this transaction, Bulis directly beneficially owned 8,077 shares of common stock.
• On December 30, 2025, Bulis sold an additional 936 shares of common stock at a price of $32.32 per share.
• After the second transaction, Bulis directly beneficially owned 7,141 shares of common stock.
• The transactions were made pursuant to a Rule 10b5-1 trading plan.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to insider selling, which can sometimes signal a lack of confidence or a desire to diversify holdings. While the sales were made under a 10b5-1 plan, the market often views such transactions with caution.

Negatives

• A key insider, the VP, Corporate Controller, sold a total of 2,072 shares of company common stock.
• The sales occurred at varying prices, with the second transaction on December 30, 2025, at a lower price of $32.32 compared to the first sale at $38.67.

Industry Context

Insider selling, even under a 10b5-1 plan, can sometimes be interpreted by the market as a signal regarding management's perception of future stock performance, though it is a common practice for executives to diversify holdings.

Stakeholder Impact

• Shareholders may interpret the insider selling as a potential lack of confidence in the company's future stock price performance, which could lead to negative sentiment or selling pressure on the stock.

Key Dates

Recommendation

The insider selling by a VP, Corporate Controller, while potentially for personal financial planning, introduces a cautious note. It's not a strong enough signal for a 'sell' recommendation without further context on company performance or broader market trends, but it also doesn't support a 'buy' given the insider's action. A 'hold' recommendation is appropriate, suggesting investors monitor future company developments and insider activity closely.

Keywords

Lyell Immunopharma, LYEL, Insider Trading, Form 4, Stock Sale, Veronica Sanchez Bulis, Biotechnology